

## Special Issue

# Hidradenitis Suppurativa (HS): Current and Emerging Treatments

### Message from the Guest Editor

Hidradenitis suppurativa (HS) to date remains a difficult disease for the dermatologist to manage due to gaps in knowledge about its etiology. There are few therapeutic choices for the treatment of HS. To date, the only FDA-approved drug remains Adalimumab (antiTNF $\alpha$ ).

However, recent studies on the pathogenesis of HS have made it possible to investigate new therapies.

Thanks to the many clinical trials currently underway in the future, it is hoped that therapeutic choices can be expanded. This Special Issue, entitled “Hidradenitis Suppurativa: Current and Emerging Therapies”, aims to bring together articles in which new therapies that specifically target cytokines involved in the pathogenesis of HS can be discussed. We hope that this Special Issue will expand the knowledge on this disease and invite colleagues to report their experiences.

### Keywords

- Hidradenitis Suppurativa
- treatment
- adalimumab
- secukinumab
- guselkumab
- biologic therapies
- small molecules

### Guest Editor

Dr. Claudio Marasca

Dermatology Unit, Medical Department, “Antonio Cardarelli” National Hospital, Naples, Italy

### Deadline for manuscript submissions

closed (20 February 2024)



## Journal of Clinical Medicine

an Open Access Journal  
by MDPI

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/156478](https://mdpi.com/si/156478)

*Journal of Clinical Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcm@mdpi.com](mailto:jcm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm)





# Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
jcm](https://mdpi.com/journal/jcm)



## About the Journal

### Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

---

### Editors-in-Chief

Prof. Dr. Emmanuel Andr  s

Internal Medicine Department, University Hospital Strasbourg, 67000  
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, University of  
Tokyo, Tokyo, Japan

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1  
(General Medicine)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).